Anda di sini
Formulari Ubat KKM (FUKKM)
| # | Generic Name | MDC | Category | Indications | Pres. Restrictions | Dosage |
|---|---|---|---|---|---|---|
| 241 | Calcium Carbonate 500 mg Capsule | A12AA04-121-C10-01-XXX | B | i) Hyperphosphatemia (phosphate binder) in chronic kidney disease patients ii) Calcium supplementation | None | i) Total dose of elemental calcium from calcium-based phosphate binder not to exceed 1,500 mg/day. Dosing is individualised based on serum phosphate level and according to product insert/protocol ii) 500 mg to 4g per day as calcium carbonate in 1-3 divided doses (500mg capsule contains 200mg elemental calcium) Dosing is individualised based on serum calcium level and according to product insert/protocol |
| 242 | Calcium Carbonate 500 mg Tablet | A12AA04-121-T10-01-XXX | B | i) Hyperphosphatemia (phosphate binder) in chronic kidney disease patients ii) Calcium supplementation | None | i) Total dose of elemental calcium from calcium-based phosphate binder not to exceed 1,500 mg/day. Dosing is individualised based on serum phosphate level and according to product insert/protocol ii) 500 mg to 4g per day as calcium carbonate in 1-3 divided doses (500mg capsule contains 200mg elemental calcium) Dosing is individualised based on serum calcium level and according to product insert/protocol |
| 243 | Calcium Chloride Dihydrate, Sodium Chloride, Magnesium Chloride Hexahydrate, Sodium Acetate Trihydrate,Potassium Chloride, and Malic Acid Solution | B05BB01-905-P60-02-XXX | A | Replacement of extracellular fluid losses in the case of isotonic dehydration, where acidosis is present or imminent. | None | The maximum infusion rate depends on the needs of the patient in fluid replacement and electrolytes, patient's weight, clinical condition, and biological status. Adults, elderly, adolescents:500ml-3L/24hr. Babies, children: 20ml to 100ml/kg/24 hr. |
| 244 | Calcium Disodium Edetate 200 mg Injection | V03AB03-999-P30-01-XXX | A | Lead Poisoning | None | IM (Lead encephalopathy): 1000 mg/m(2)/day IM in divided equal doses 8 to 12 hours apart, for 5 days. Therapy is interrupted for 2 to 4 days, and followed by an additional 5-day course of therapy, if indicated. Do not exceed the recommended daily dosage. IV: 1000 mg/m(2)/day administered IV over 8 to 12 hours for 5 days. Therapy is interrupted for 2 to 4 days, and followed by an additional 5-day course of therapy, if indicated. |
| 245 | Calcium Gluconate 10% Injection | A12AA03-000-P30-01-XXX | B | i)Acute hypocalcaemia ii)Hypocalcaemic tetany iii)Cardiac resuscitation | None | i) ADULT: 1 to 2 g (2.2 to 4.4 mmol). CHILD: 50mg/kg/dose (0.5ml/kg/dose) IV short infusion over at least 10 to 20 minutes, per dose. Max: 20ml per dose; ii) ADULT: 1g (2.2 mmol) by slow IV injection followed by continuous infusion of 4 g (8.8 mmol) daily; iii) IV or intracardiac injection, 1g (2.2mmol). Dosing is individualised and according to product insert/protocol. |
| 246 | Calcium Lactate 300 mg Tablet | A12AA05-125-T10-01-XXX | C | For prophylaxis of calcium deficiency and treatment of chronic hypocalcaemia | None | ADULT: 300mg - 600mg (as elemental Ca) daily in in divided doses; Dosing is individualised and according to product insert/protocol |
| 247 | Calcium Polystyrene Sulphonate Powder | V03AE01-999-F21-01-XXX | A*, A/KK | PRESCRIBER CATEGORY A*: Hyperkalemia resulting from acute or chronic renal failure PRESCRIBER CATEGORY A/KK: For asymptomatic mild hyperkalemia without ECG changes | None | ADULT: 15 – 30g daily in 2-3 divided doses. Each dose should be suspended in 30 – 50ml of water and administered orally at least 3 hours before or 3 hours after other oral medications. CHILD: 0.125-0.25g/kg orally or rectally 4 times per day (max: 10g/dose). NEONATE: 0.125-0.25g/kg rectally 4 times/day. Evacuate the resin 8-12 hours after the last dose with glycerine enema. (Oral route is CONTRAINDICATED in neonates). Dosing is individualised and according to product insert/protocol |
| 248 | Calfactant 35mg/ml intratracheal suspension | R07AA02-000-L91-04-XXX | A* | For the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS and for the treatment (“rescue”) of premature infants who develop RDS. Prophylaxis: Indicated for premature infants <29 weeks of gestational age at significant risk for RDS. Should be administered as soon as possible, preferably within 30 minutes after birth. Treatment: Indicated for infants ≤72 hours of age with RDS (confirmed by clinical and radiologic findings) and requiring endotracheal intubation. | None | 3mL/kg body weight at birth to be administered every 12 hours for total up to 3 doses. |
| 249 | Capecitabine 150 mg Tablet | L01BC06000T1002XX | A* | i) Metastatic breast cancer; ii) Treatment of colorectal cancer in adjuvant and metastatic setting; iii) advanced oesophagogastric cancer in combination with a platinum-based regimen. | i. As monotherapy or in combination with docetaxel: 1250 mg/m2 twice daily for 2 weeks followed by a 7-day rest period. ii. As monotherapy: 1250 mg/m2 twice daily (morning and evening) for 2 weeks, followed by a 7-day rest period. As combination: 1000 mg/m2 twice daily for 2 weeks followed by a 7-day rest period. iii. In combination with a platinum: 1000 mg/m2 twice daily for 14 days followed by a 7 day rest period. Dosing is individualised and according to product insert/ treatment protocol. | |
| 250 | Capecitabine 500 mg Tablet | L01BC06000T1001XX | A* | i) Metastatic breast cancer; ii) Treatment of colorectal cancer in adjuvant and metastatic setting; iii) advanced oesophagogastric cancer in combination with a platinum-based regimen. | i. As monotherapy or in combination with docetaxel: 1250 mg/m2 twice daily for 2 weeks followed by a 7-day rest period. ii. As monotherapy: 1250 mg/m2 twice daily (morning and evening) for 2 weeks, followed by a 7-day rest period. As combination: 1000 mg/m2 twice daily for 2 weeks followed by a 7-day rest period. iii. In combination with a platinum: 1000 mg/m2 twice daily for 14 days followed by a 7 day rest period. Dosing is individualised and according to product insert/ treatment protocol. | |
| 251 | Captopril 25 mg Tablet | C09AA01000T1002XX | B | i) Hypertension ii) Congestive heart failure iii) Post-myocardial infarction iv) Diabetic kidney disease | None | i) Initial: 25-75mg in 2-3 divided doses Maintenance: 100-150mg in 2-3 divided doses ii) Initial: 6.25-12.5mg 2-3 times daily Maintenance: 75-150mg daily in divided doses iii) Initial: 6.25mg followed by 12.5mg and then 25mg Maintenance: 75-150mg daily in 2-3 divided doses iv) 75-100 mg in divided doses Dosing is individualised and according to product insert / protocol. |
| 252 | Carbachol 0.01% Intraocular Solution | S01EB02-100-D20-01-XXX | A | For intraocular use for miosis during surgery | None | Instill no more than 0.5 ml gently into the anterior chamber |
| 253 | Carbamazepine 100 mg/5 ml (2% w/v) Syrup | N03AF01-000-L90-01-XXX | A | Epilepsy | None | ADULT: Initially, 100-200 mg once or twice daily gradually increased by increments of 100-200 mg every 2 week. Maintenance: 0.8-1.2 g daily in divided doses. Max: Adult: 1.6 g daily CHILD: 10-15 years: 0.6-1 g daily 5-10 years: 400-600 mg daily 1-5 years: 200-400 mg daily less than or equal to 1 year: 100-200 mg daily. Alternatively, 10-20 mg/kg body weight daily in divided doses. |
| 254 | Carbamazepine 200 mg CR Tablet | N03AF01-000-T50-01-XXX | A | i) Epilepsy ii) Trigeminal Neuralgia iii) Idiopathic glossopharyngeal neuralgia iv) Acute mania and maintenance of bipolar affective disorder to prevent or attenuate recurrence | None | ADULT: Initial, 200 mg twice daily for the first week, may increase dosage by 200 mg/day at weekly intervals until optimal response is obtained. Maximum 1.6 g/day. CHILD: usual maximum dosage 1000 mg/day in children 12-15 years of age, 1200 mg/day in patients above 15 years of age |
| 255 | Carbamazepine 200 mg Tablet | N03AF01-000-T10-01-XXX | B | i) Epilepsy ii) Trigeminal neuralgia | i) ADULT: 100 - 200 mg 1 - 3 times daily increased gradually to usual dose of 0.8 - 1.2 g daily in divided doses. CHILD: Up to 1 year: 100 - 200 mg daily 1 - 5 yrs: 200 - 400 mg daily 5 - 10 years: 400 - 600 mg daily 10 - 15 years: 0.6 - 1 g daily ii) The initial dosage of 200 to 400mg should be slowly raised daily until freedom from pain is achieved (normally at 200mg 3 to 4 times daily). The dosage should then be gradually reduced to the lowest possible maintenance level. In elderly patients, an initial dose of 100mg twice daily is recommended. | |
| 256 | Carbamazepine 400 mg CR Tablet | N03AF01-000-T50-02-XXX | A | i) Epilepsy ii) Trigeminal Neuralgia iii) Idiopathic glossopharyngeal neuralgia iv) Acute mania and maintenance of bipolar affective disorder to prevent or attenuate recurrence | None | ADULT: Initial, 200 mg twice daily for the first week, may increase dosage by 200 mg/day at weekly intervals until optimal response is obtained. Maximum 1.6 g/day. CHILD: usual maximum dosage 1000 mg/day in children 12-15 years of age, 1200 mg/day in patients above 15 years of age |
| 257 | Carbamide (Urea) 10 % Cream | D02AE01000G1001XX | B | Contact irritant dermatitis, infantile eczemas, acute and chronic allergic eczemas, icthyosis, hyperkeratotic | Apply sparingly and rub into affected area 2 - 3 times daily and when required after cleansing skin | |
| 258 | Carbetocin 100 mcg/ ml Injection | H01BB03-000-P20-01-XXX | A* | Prevention of uterine atony and postpartum hemorrhage following elective cesarean section under epidural or spinal anaesthesia | A single IV dose of 100mcg (1ml) is adminitered by bolus injection, slowly over 1minute, only when delivery of the infant has been completed by caesarean section under epidural or spinal anaesthesia, before or after delivery of the placenta. | |
| 259 | Carbimazole 5 mg Tablet | H03BB01000T1001XX | B | Hyperthyroidism | ADULT: Initially, 10-60mg daily in divided doses given 8 hourly. Maintenance: 5 to 20mg daily. CHILDREN > 6 years: Initially 15mg daily in divided doses. CHILDREN 1-6 years: Initially 7.5mg daily in divided doses | |
| 260 | Carboplatin 10mg/mL Injection | L01XA02000P4001XX | A* | i) Solid tumours; ii) Salvage therapy for lymphoma | 360 - 400 mg/m2 BSA, by IV infusion over 15 mins to 1 hour on Day 1 every 4 weeks. Alternatively, prescription may be based on Area Under Curve (AUC) calculations. CHILD: 500-600 mg/m2 over 1 hour once every 3 weeks. Salvage regimes in lymphomas - refer to specific protocols. Starting dose in renal impairment, please refer to product insert. | |
| 261 | Carboprost Tromethamine 250mcg Injection | G02AD04-999-P30-01XXX | A* | Treatment of refractory postpartum haemorrhage unresponsive to conventional methods of management. | None | Initially 250 mcg deep IM inj. The dose may be repeated at intervals of 15-90 min if necessary. Max total dose: 2000 mcg (8 doses). |
| 262 | Cardioplegia solution containing Potassium Chloride, Magnesium chloride & Procaine HCl Injection | B05XA16-934-P30-01-XXX | A* | For myocardial preservation(prevent myocardial damage) during cardiac surgery | None | Dilute 20 ml to 1 L of Ringer solution (cooled to 2-8 ∞C prior to use). Initial rapid instillation into aortic root at 300 ml/m≤ body surface area/min for 3 minutes. Should myocardial activity persist or recur instill at 300ml/m≤ body surface area/min for 2 minutes |
| 263 | Carvedilol 25mg Tablet | C07AG02-000-T10-02-XX | A/KK | i) Treatment of all patients with stable and symptomatic, mild, moderate and severe chronic heart failure in combination with ACEis and diuretics ii) Hypertension iii) Angina pectoris | None | i) Initial: 3.125mg twice daily for 2 weeks Maintenance: Titrate up to as tolerated Max: <85 kg: 25 mg twice daily >85 kg: 50 mg twice daily ii) Initial: 12.5mg once daily Maintenance: 25mg once daily Max. 50mg daily in 1 or 2 divided doses iii) Initial: 12.5mg once daily Maintenance: 25mg once daily Max. 100mg daily in 1 or 2 divided doses Dosing is individualised and according to product insert / protocol. |
| 264 | Carvedilol 6.25mg Tablet | C07AG02-000-T10-01-XX | A/KK | i) Treatment of all patients with stable and symptomatic, mild, moderate and severe chronic heart failure in combination with ACEis and diuretics ii) Hypertension iii) Angina pectoris | None | i) Initial: 3.125mg twice daily for 2 weeks Maintenance: Titrate up to as tolerated Max: <85 kg: 25 mg twice daily >85 kg: 50 mg twice daily ii) Initial: 12.5mg once daily Maintenance: 25mg once daily Max. 50mg daily in 1 or 2 divided doses iii) Initial: 12.5mg once daily Maintenance: 25mg once daily Max. 100mg daily in 1 or 2 divided doses Dosing is individualised and according to product insert / protocol. |
| 265 | Caspofungin Acetate 50 mg Injection | J02AX04-122-P40-01-XXX | A* | i) Confirmed systemic fungal infection in patients who are refractory or intolerant to other fungal therapies. ii) For pediatric patient (12 month and older) for the following indications : a) Empirical therapy for presumed fungal infections in febrile, neutropenic patients b) Treatment of invasive candidiasis, including candidemia and the following Candida infections ; intra-abdominal abscesses, peritonitis and pleural space infections c) Treatment of esophageal candidiasis d) Treatment of invasive Aspergillosis in patients who are refractory to or intolerant of others therapy (eg : Amphotericin B) | None | i) Invasive aspergillosis & invasive candidiasis: ADULT: Initially, 70 mg infused over 1 hour followed by subsequent doses of 50 mg/day. Oesophageal candidiasis: ADULT: 50 mg by slow IV infusion over approximately 1 hour ii) For all indications, a loading dose of 70mg/m2 on D1 followed by maintenance dose of 50mg/m2 od. |
| 266 | Caspofungin Acetate 70 mg Injection | J02AX04-122-P40-02-XXX | A* | i) Confirmed systemic fungal infection in patients who are refractory or intolerant to other fungal therapies. ii) For pediatric patient (12 month and older) for the following indications : a) Empirical therapy for presumed fungal infections in febrile, neutropenic patients b) Treatment of invasive candidiasis, including candidemia and the following Candida infections ; intra-abdominal abscesses, peritonitis and pleural space infections c) Treatment of esophageal candidiasis d) Treatment of invasive Aspergillosis in patients who are refractory to or intolerant of others therapy (eg : Amphotericin B) | None | i) Invasive aspergillosis & invasive candidiasis: ADULT: Initially, 70 mg infused over 1 hour followed by subsequent doses of 50 mg/day. Oesophageal candidiasis: ADULT: 50 mg by slow IV infusion over approximately 1 hour daily ii) Child (12months to 17 years) : For all indication) A single 70mg/m2 loading dose (not to exceed an actual dose of 70mg) by slow IV infusion over 1hour; followed by 50mg/m2 (not to exceed an actual dose of 70mg) |
| 267 | Cefaclor 125mg/5ml Suspension | J01DC04-000-F21-01-XXX | A | Infections caused by susceptible organisms including Staphylococcus aureus and H. influenzae, treatment of sinusitis and infections involving the respiratory tract, skin and skin structure, bone and joint, and urinary tract | CHILD:>1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid. Maximum: 1 g daily | |
| 268 | Cefaclor 500mg Capsule | J01DC04-000-C10-02-XXX | A | Infections caused by susceptible organisms including Staphylococcus aureus and H. influenzae, treatment of sinusitis and infections involving the respiratory tract, skin and skin structure, bone and joint, and urinary tract | None | ADULT: 250 mg 3 times daily for 10 days. For severe infections, double the dosage. Maximum: 4 g daily. CHILD:>1 mth: 20 mg/kg daily in 3 divided doses, increased to 40 mg/kg daily if necessary, <1 yr: 62.5 mg tid, 1-5 yr: 125 mg tid, >5 yr: 250 mg tid . Maximum: 1 g daily |
| 269 | Cefazolin Sodium 1g Injection | J01DB04-520-P30-01-XXX | A | Infection caused by cefazolin-sensitive microorganism, infection of the respiratory tract, urogenital tract, skin and soft tissue, bile duct, bones and joint, endocarditis, systemic septic infection, peri-operative/ surgical prophylaxis | None | ADULT: Uncomplicated infections: 500 - 1000 mg 2 - 3 times daily. Moderately severe and severe infections: 500 - 1000 mg 3 - 4 times daily. Severe life-threatening infections: 1 - 1.5 g 4 times daily. Rarely, dose up to 12 g daily. CHILDREN >1 month: 25-50mg/kg/day in 3-4 divided dose |
| 270 | Cefepime 1g Injection | J01DE01-110-P40-02-XXX | A* | Febrile neutropenia, septicaemia, lower respiratory tract infection, urinary tract infection, skin and skin structure infections, gynaecologic and intra-abdominal infections | None | ADULT: 1 - 2 g twice daily for most infections. For severe infections including febrile neutropenia: 2 g 3 times daily. CHILD:2 mth - 16 yr: ≤40 kg: 50 mg/kg every 8-12 hr for 7-10 days |